• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Safeguard Scientifics Announces Second Quarter 2023 Financial Results

    8/10/23 4:10:50 PM ET
    $SFE
    Finance/Investors Services
    Finance
    Get the next $SFE alert in real time by email

    RADNOR, Pa., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Safeguard Scientifics, Inc. (NASDAQ:SFE) ("Safeguard" or the "Company") today announced financial results for the three and six months ended June 30, 2023.

    SECOND QUARTER 2023 HIGHLIGHTS

    • Financial Results
      • Cash, cash equivalents and restricted cash totaled $15.1 million at June 30, 2023.
      • The carrying value of the Company's ownership interests totaled $13.0 million at June 30, 2023. The total cost of the Company's ownership interests was $138.4 million.
      • Net loss for the three months ended June 30, 2023 was $2.9 million, or $0.18 per share, as compared with a net income of $0.5 million, or $0.03 per share, for the same period in 2022.
      • Net loss for the six months ended June 30, 2023 was $6.3 million, or $0.39 per share, as compared with a net loss of $6.2 million, or $0.38 per share, for the same period in 2022.



    • Exits & Deployments
      • Safeguard deployed $3.0 million to Prognos as part of a financing round consisting of existing and new investors.
      • Safeguard received $0.4 million of cash proceeds from the secondary sale of a subordinated promissory note issued by Aktana. In a separate transaction, Aktana completed a recapitalization transaction in which Safeguard declined to participate resulting in Safeguard having no remaining material ownership position in Aktana.
      • Subsequent to the quarter, Trice Medical completed a recapitalization transaction in which Safeguard declined to participate that resulted in Safeguard retaining a small, subordinated debt position and a di minimis ownership interest.



    • Safeguard Company Performance
      • The aggregate trailing twelve-month revenues ending March 31, 2023 for six of Safeguard's companies, which excludes the Other Ownership Interests, was $95 million, an increase of 12.8% from the comparable prior period.



    • Operating Costs
      • General and administrative expenses totaled $1.2 million for the quarter ended June 30, 2023 as compared to $1.1 million for the comparable period of 2022, a 3.5% increase. General and administrative expenses were $2.4 million for the six-month periods ended June 30, 2023 and 2022.
      • Safeguard also continued to lower its corporate expenses,1 which totaled $0.7 million for the quarter ended June 30, 2023, as compared to $0.8 million for the comparable period of 2022, a decrease of 12.2%. Corporate expenses were $1.5 million for the six months ended June 30, 2023 as compared to $1.7 million for the comparable period of 2022.



    • Outlook
      • Safeguard is no longer in discussions regarding a potential strategic transaction with the counterparty it disclosed last quarter due to, among other things, certain valuation, tax and structural issues that were fundamental to the transaction. While other strategic transactions could still be considered, Safeguard is currently planning to return excess cash to shareholders in Q4 2023.
      • Excess cash represents cash on hand less the amounts required to be retained to support the operations of the Company, satisfy its liabilities and pay one-time costs incurred as a result of pursuing this strategy. While subject to change, and assuming a substantial reduction in operational costs as noted below, the excess cash is currently estimated to be approximately half of our cash balance in Q4 2023.
      • In addition, in order to substantially reduce its ongoing operating costs, Safeguard is exploring delisting from Nasdaq and becoming a non-reporting company, which would be subject to shareholder approval.
      • Safeguard estimates that the exit values from the remaining portfolio companies, assuming normal conditions and ordinary course exits, would range between $25 million and $45 million over the next two years.
      • Safeguard's year to date follow on deployments in the portfolio totals $3.3 million and we do not expect to make additional deployments to the portfolio.
      • Safeguard will continue to closely manage corporate expenses for the remainder of 2023. We expect to be below $3.0 million, the low end of the range previously estimated for the year.

    "While we are disappointed that our strategic process did not result in a transaction, we are working diligently on a plan to return excess cash to our shareholders in Q4 2023, materially reduce our ongoing operating costs, and allow the remaining portfolio companies to exit over the next two years," said Eric C. Salzman, Chief Executive Officer.

    __________________

    1 Corporate expenses are general and administrative expenses excluding depreciation, severance, stock-based compensation and other non-recurring items. See full reconciliation in the financial section of this statement.



    OWNERSHIP INTERESTS AT JUNE 30, 2023

    CompaniesCategoryAcquisition

    Year
    Primary

    Ownership%
    Fully Diluted

    Ownership%


    **
    Carrying

    Value

    (in millions)
     Cost

    (in millions)
            
            
    Revenue of $5 million to $10 million

            
    MoxeHealthcare201619.3%18.0% 5.8  7.5
    Revenue of $10 million to $20 million

            
    Clutch Holdings, Inc.Digital Media201341.7%33.3% 1.5  18.3
    InfoBionic, Inc.Healthcare201425.2%22.1% -  22.0
    Syapse, Inc.Healthcare201411.0%8.8% -  26.6
    Prognos Health, Inc. +Healthcare201119.4%17.8% 4.5  17.6
    Revenue of $20 million to $30 million

            
              
    meQuilibrium ++Healthcare201531.3%21.1% -  14.5
    Trice Medical, Inc. *Healthcare201411.6%8.7% -  12.2
    Other Ownership Interests

            
    All othersVarious    1.2  19.7
        TOTAL:$13.0 $138.4

    * Subsequent to the quarter, Trice Medical completed a recapitalization transaction resulting in Safeguard retaining a small subordinated debt position and a di minimis ownership interest.

    + Company dropped into a lower revenue category this quarter.

    ++ Company progressed into a higher revenue category this quarter.

    ** Based on information provided by each respective company. Assumes the conversion or exercise of all currently outstanding securities including the issuance of all shares available under authorized employee equity programs. Does not reflect liquidation preferences, priority payments, proceeds from option and/or warrant exercises or other company-specific transaction-related obligations in a liquidation or exit transaction.



    CONFERENCE CALL AND WEBCAST DETAILS

    Please call 10-15 minutes prior to the call to register.

    Date:   August 10, 2023

    Time:   5:00 p.m. ET

    Webcast:   https://www.webcast-eqs.com/register/safeguardscientific081023/en

    Live Number:   877-407-0989

    Speakers:   Chief Executive Officer, Eric C. Salzman; and Senior Vice President and Chief Financial Officer, Mark A. Herndon

    Format:   Discussion of the second quarter's financial results followed by Q&A

    The replay will be available at Safeguard.com's investor relations site under "Past events". For more information please contact [email protected]. 

    About Safeguard Scientifics

    Historically, Safeguard Scientifics has provided capital and relevant expertise to fuel the growth of technology-driven businesses. Safeguard has a distinguished track record of fostering innovation and building market leaders that spans more than six decades. Safeguard is currently pursuing a focused strategy to value-maximize and monetize its ownership interests over a multi-year time frame to drive shareholder value. For more information, please visit www.safeguard.com.

    Forward-Looking Statements

    Except for the historical information and discussions contained herein, statements contained in this release may constitute "forward-looking statements" within the meaning of the federal securities laws. Our forward-looking statements are subject to risks and uncertainties. Forward-looking statements include, but are not limited to, statements regarding Safeguard's ability to maximize the value of monetization opportunities of its ownership interests and drive total shareholder returns, Safeguard's initiatives, including, without limitation, taken or contemplated to enhance and unlock value for all of its shareholders, Safeguard's efforts to execute on and implement its strategy to streamline its organizational structure, reduce its operating costs, pursue monetization opportunities for ownership interests and maximize the return of value to its shareholders, Safeguard's ability to create, unlock, enhance and maximize shareholder value, the effect of Safeguard's management succession plan on driving increased organizational effectiveness and efficiencies, the ability of the management team to execute Safeguard's strategy, the availability of, the timing of, and the proceeds that may ultimately be derived from the monetization of ownership interests, Safeguard's projections regarding the reduction in its ongoing operating expenses, Safeguard's projections regarding annualized operating expenses and expected severance expenses, monetization opportunities for ownership interests, and the amount of net proceeds from the monetization of ownership interests that will enable the return of value to Safeguard shareholders after satisfying working capital needs and the timing of such return of value. Such forward-looking statements are not guarantees of future operational or financial performance and are based on current expectations that involve a number of uncertainties, risks and assumptions that are difficult to predict. Therefore, actual outcomes and/or results may differ materially from those expressed or implied by such forward-looking statements. The risks and uncertainties that could cause actual results to differ materially include, among others, our ability to make good decisions about the monetization of our ownership interests for maximum value or at all and the return of value to our shareholders, our ability to successfully execute on our strategy to streamline our organizational structure and align our cost structure to increase shareholder value, whether our strategy will better position us to focus our resources on the highest-return opportunities and deliver enhanced shareholder value, the ongoing support of our existing ownership interests, the fact that our companies may vary from period to period, challenges to achieving liquidity from our ownership interests, fluctuations in the market prices of our publicly traded holdings, if any, competition, our inability to obtain maximum value for our ownership interests, our ability to attract and retain qualified employees, market valuations in sectors in which our ownership interests operate, our inability to control our ownership interests, our need to manage our assets to avoid registration under the Investment Company Act of 1940, risks, disruption, costs and uncertainty caused by or related to the actions of activist shareholders, including that if individuals are elected to our Board with a specific agenda, it may adversely affect our ability to effectively implement our business strategy and create value for our shareholders and perceived uncertainties as to our future direction as a result of potential changes to the composition of our Board may lead to the perception of a change in the direction of our business, instability or a lack of continuity that may adversely affect our business, and risks associated with our ownership interests, including the fact that most of our ownership interests have a limited operating history and a history of operating losses, face intense competition and may never be profitable, the effect of economic conditions in the business sectors in which our companies operate, and other uncertainties described in our filings with the Securities and Exchange Commission. Many of these factors are beyond our ability to predict or control. As a result of these and other factors, the Company's past operational and financial performance should not be relied on as an indication of future performance. Further information on the above risk factors and other potential factors that could affect our future business, operating results and financial condition is included in our Annual Report on Form 10-K for the year ended December 31, 2022 and other periodic filings with the Securities and Exchange Commission, including risks under the heading "Risk Factors." The Company does not assume any obligation to update any forward-looking statements or other information contained in this press release.

    ###

    SAFEGUARD CONTACT:

    Mark Herndon

    Chief Financial Officer

    (610) 975-4913

    [email protected]

     
    Safeguard Scientifics, Inc.

    Condensed Consolidated Balance Sheets

    (in thousands)
     
      June 30, 2023  December 31, 2022 
    Assets        
    Cash, cash equivalents, restricted cash and marketable securities $15,112  $19,312 
    Ownership interests  —   860 
    Other current assets  1,615   1,251 
    Total current assets  16,727   21,423 
    Ownership interests in and advances  12,972   14,545 
    Other assets  1,383   1,724 
    Total Assets $31,082  $37,692 
             
    Liabilities and Equity        
    Other current liabilities $1,256  $1,817 
    Total current liabilities  1,256   1,817 
    Lease liability - non-current  1,013   1,249 
    Other long-term liabilities  50   50 
    Total equity  28,763   34,576 
    Total Liabilities and Equity $31,082  $37,692 



     
    Safeguard Scientifics, Inc.

    Condensed Consolidated Statements of Operations

    (in thousands, except per share amounts)
     
      Three Months Ended  Six Months Ended 
      June 30,  June 30, 
      2023  2022  2023  2022 
    Operating expenses $1,186  $1,146  $2,371  $2,380 
    Operating loss  (1,186)  (1,146)  (2,371)  (2,380)
    Other income (loss), net  (166)  30   (175)  (1,967)
    Interest, net  249   145   523   246 
    Equity income (loss), net  (1,759)  1,454   (4,323)  (2,125)
    Net income (loss) before income taxes  (2,862)  483   (6,346)  (6,226)
    Income tax benefit (expense)  —   —   —   — 
    Net income (loss) $(2,862) $483  $(6,346) $(6,226)
    Net income (loss) per share:                
    Basic $(0.18) $0.03  $(0.39) $(0.38)
    Diluted $(0.18) $0.03  $(0.39) $(0.38)
    Weighted average shares used in computing income (loss) per share:                
    Basic  16,143   16,356   16,108   16,468 
    Diluted  16,143   16,356   16,108   16,468 
                     
                     

     Safeguard Scientifics, Inc.

    Financial Data

    (in thousands)

    Additional Financial Information

    Non-GAAP Measures

    In discussing financial results and guidance, the Company refers to the measure "corporate expenses" which is not in accordance with Generally Accepted Accounting Principles (GAAP). We use this non-GAAP financial measure internally to make operating and strategic decisions, including evaluating our overall performance and as a factor in determining compensation for certain employees. We have defined corporate expenses as general and administrative costs excluding stock based compensation, severance costs, and non-recurring items and other. Non-recurring items and other includes accruals related to the Company's LTIP plan that will not be paid until reaching a specified threshold within that plan as well as costs incurred for exploring strategic alternatives. We believe presenting this non-GAAP financial measure provides additional information to facilitate comparison of our historical operating costs and their trends, and provides additional transparency on how we evaluate our cost structure. We also believe presenting this measure allows investors to view our performance using the same measure that we use in evaluating our performance and trends.

    Corporate expenses reconciliation:

      Three Months Ended  Six Months Ended 
      June 30,  June 30, 
      2023  2022  2023  2022 
    Corporate expenses $730  $831  $1,521  $1,676 
    Stock based compensation  278   262   570   576 
    Non-recurring items and other  178   53   280   128 
    General and administrative expenses $1,186  $1,146  $2,371  $2,380 





    Primary Logo

    Get the next $SFE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SFE

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SFE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Safeguard Scientifics Filed Form 25 to Voluntarily Delist its Common Stock from The Nasdaq Stock Market LLC

      RADNOR, Pa., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Safeguard Scientifics, Inc. (NASDAQ:SFE) ("Safeguard" or the "Company") has announced today that it filed Form 25 with the Securities and Exchange Commission (the "SEC") to voluntarily delist its shares of common stock from trading on The Nasdaq Stock Market LLC ("Nasdaq") in connection with its previously announced plan to deregister its common stock under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and to delist the Company's common stock from trading on Nasdaq (referred to as the "Transaction"). The Company expects that the delisting will occur ten days after the filing of Form 25 so that trading will be suspended

      2/2/24 8:30:00 AM ET
      $SFE
      Finance/Investors Services
      Finance
    • Safeguard Scientifics Intends to File Form 25 to Voluntarily Delist its Common Stock from The Nasdaq Stock Market LLC

      Radnor, Pa, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Safeguard Scientifics, Inc. (NASDAQ:SFE) ("Safeguard" or the "Company") has announced today that it notified The Nasdaq Stock Market LLC ("Nasdaq") that it intends to file Form 25 with the Securities and Exchange Commission (the "SEC") on February 2, 2024 to voluntarily delist its shares of common stock from trading on Nasdaq in connection with its previously announced plan to deregister its common stock under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The Company expects that the delisting will occur ten days after the filing of Form 25, at which point, the Company intends to file a Form 15 with the SEC certifying

      1/22/24 4:30:00 PM ET
      $SFE
      Finance/Investors Services
      Finance
    • Safeguard Scientifics Announces Effective Date of Stock Splits to Effectuate the Going Dark Transaction and New Chief Executive Officer and Chief Financial Officer

      RADNOR, Pa., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Safeguard Scientifics, Inc. (NASDAQ:SFE) ("Safeguard" or the "Company") today announced that, as authorized by its Board of Directors (the "Board"), the Company will file amendments to its articles of incorporation with the Pennsylvania Department of State to effectuate a reverse stock split at a ratio of 1-for-100, to be followed immediately by a forward stock split at a ratio of 100-for-1 (collectively referred to as "stock splits"), which are expected to become effective on or about January 12, 2024, and the Company's common stock is expected to begin trading on The Nasdaq Stock Market LLC ("Nasdaq") on a post-forward stock split basis upon

      1/5/24 4:30:00 PM ET
      $SFE
      Finance/Investors Services
      Finance

    $SFE
    Leadership Updates

    Live Leadership Updates

    See more
    • TheracosBio Announces the Appointments of Jim Greenwood to Board of Directors and Jeff McGroarty as Chief Financial Officer

      TheracosBio today announced the appointment of former US Congressman Jim Greenwood to the Board of Directors of its parent company and Jeff McGroarty, MBA, as its Chief Financial Officer. Congressman Greenwood is an established leader in life sciences across business and public policy, and Mr. McGroarty has served as a CFO of public and private life sciences and technology companies. Both newly appointed team members will help shape the commercial strategy for Brenzavvy™ (bexagliflozin), a recently FDA-approved treatment for type 2 diabetes. "Accomplished leaders, Jim and Jeff will be valuable members of our team at this critical time for TheracosBio," said Albert R. Collinson, Ph.D., Pres

      3/13/23 8:00:00 AM ET
      $ANVS
      $SFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Finance/Investors Services
      Finance
    • Safeguard Scientifics Announces Appointment Of Eric C. Salzman As CEO

      RADNOR, Pa., Dec. 21, 2020 /PRNewswire/ -- Safeguard Scientifics, Inc. (NYSE:SFE) announced today that Eric C. Salzman has been appointed Chief Executive Officer, effective December 21, 2020.  Since April 1, 2020, Mr. Salzman has served as the Company's Chief Restructuring Officer. As CEO, Mr. Salzman will continue to focus on the value maximization and monetization of Safeguard's interests in its portfolio companies as well as the management of Safeguard's operations. "Since joining Safeguard earlier this year, we have been impressed with Eric's progress towards executing on Safeguard's strategy to drive value creation from the portfolio and return capital to our shareholders," said Robe

      12/21/20 8:00:00 AM ET
      $SFE
      Finance/Investors Services
      Finance

    $SFE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Manko Joseph M. Jr. was granted 38,087 shares, increasing direct ownership by 20% to 232,323 units (SEC Form 4)

      4 - SAFEGUARD SCIENTIFICS INC (0000086115) (Issuer)

      2/1/24 2:36:21 PM ET
      $SFE
      Finance/Investors Services
      Finance
    • Demont Ross D was granted 20,775 shares, increasing direct ownership by 8% to 287,256 units (SEC Form 4)

      4 - SAFEGUARD SCIENTIFICS INC (0000086115) (Issuer)

      1/31/24 9:19:37 AM ET
      $SFE
      Finance/Investors Services
      Finance
    • Michelson Beth was granted 22,506 shares, increasing direct ownership by 22% to 126,352 units (SEC Form 4)

      4 - SAFEGUARD SCIENTIFICS INC (0000086115) (Issuer)

      1/31/24 9:09:45 AM ET
      $SFE
      Finance/Investors Services
      Finance

    $SFE
    SEC Filings

    See more
    • SEC Form 15-12G filed by Safeguard Scientifics Inc.

      15-12G - SAFEGUARD SCIENTIFICS INC (0000086115) (Filer)

      2/20/24 3:02:10 PM ET
      $SFE
      Finance/Investors Services
      Finance
    • SEC Form SC 13E3/A filed by Safeguard Scientifics Inc. (Amendment)

      SC 13E3/A - SAFEGUARD SCIENTIFICS INC (0000086115) (Subject)

      2/20/24 3:01:28 PM ET
      $SFE
      Finance/Investors Services
      Finance
    • SEC Form EFFECT filed by Safeguard Scientifics Inc.

      EFFECT - SAFEGUARD SCIENTIFICS INC (0000086115) (Filer)

      2/20/24 12:15:21 AM ET
      $SFE
      Finance/Investors Services
      Finance

    $SFE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Safeguard Scientifics Inc. (Amendment)

      SC 13G/A - SAFEGUARD SCIENTIFICS INC (0000086115) (Subject)

      2/14/24 5:04:07 PM ET
      $SFE
      Finance/Investors Services
      Finance
    • SEC Form SC 13G/A filed by Safeguard Scientifics Inc. (Amendment)

      SC 13G/A - SAFEGUARD SCIENTIFICS INC (0000086115) (Subject)

      2/14/24 4:05:40 PM ET
      $SFE
      Finance/Investors Services
      Finance
    • SEC Form SC 13G/A filed by Safeguard Scientifics Inc. (Amendment)

      SC 13G/A - SAFEGUARD SCIENTIFICS INC (0000086115) (Subject)

      2/12/24 4:59:41 PM ET
      $SFE
      Finance/Investors Services
      Finance

    $SFE
    Financials

    Live finance-specific insights

    See more
    • Safeguard Scientifics Announces Stock Split Ratios to Effectuate the Going Dark Transaction

      RADNOR, Pa., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Safeguard Scientifics, Inc. (NASDAQ:SFE) ("Safeguard" or the "Company") today announced that, after the Company's shareholders adopted amendments to the articles of incorporation at the Special Meeting of Shareholders held on December 15, 2023 (the "Special Meeting") to effect a reverse stock split, to be followed immediately by a forward stock split, at a ratio of (i) not less than 1-for-50 and not greater than 1-for-100, in the case of the reverse stock split, and (ii) not less than 50-for-1 and not greater than 100-for-1, in the case of the forward stock split (collectively referred to as "stock splits"), the Company's Board of Directors (t

      12/18/23 4:30:00 PM ET
      $SFE
      Finance/Investors Services
      Finance
    • Safeguard Scientifics' Board of Directors Declares Contingent Cash Dividend of $0.35 Per Share

      RADNOR, Pa., Dec. 08, 2023 (GLOBE NEWSWIRE) -- Safeguard Scientifics, Inc. (NASDAQ:SFE) ("Safeguard" or the "Company") today announced that on December 7, 2023, its Board of Directors (the "Board") declared a special cash dividend of $0.35 per share, payable on December 28, 2023 to shareholders of record as of the close of business on December 19, 2023 (the "Record Date"). The dividend is contingent on the adoption of amendments to the Company's articles of incorporation effecting the reverse stock split and the forward stock split of the Company's common stock at the Special Meeting of Shareholders to be held on December 15, 2023, and the Board thereafter giving effect to the Company's

      12/8/23 4:30:00 PM ET
      $SFE
      Finance/Investors Services
      Finance
    • Safeguard Scientifics Announces Third Quarter 2023 Financial Results

      RADNOR, Pa., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Safeguard Scientifics, Inc. (NASDAQ:SFE) ("Safeguard" or the "Company") today announced financial results for the three and nine months ended September 30, 2023. THIRD QUARTER 2023 HIGHLIGHTS Financial Results Cash, cash equivalents and restricted cash totaled $15.7 million at September 30, 2023.The carrying value of the Company's ownership interests totaled $14.8 million at September 30, 2023. The total cost of the Company's ownership interests was $122.8 million.Net income for the three months ended September 30, 2023 was $0.9 million, or $0.06 per basic and fully diluted share, as compared with a net loss of $3.2 million, or $0.19 per bas

      11/2/23 4:30:03 PM ET
      $SFE
      Finance/Investors Services
      Finance